On 6 November 2024, Celltrion announced that it participated in the World ADC 2024 conference where it unveiled preclinical study results of two new antibody-drug conjugate (ADC) candidates – CT-P70 and CT-P71.
CT-P70 and CT-P71 are ADC treatments designed to target solid cancers; with CT-P70 focussing on non-small cell lung cancer (NSCLC) and CT-P71 aiming to treat bladder cancer. According to Celltrion, the results demonstrate that CT-P71 had relatively superior therapeutic effects compared to competing drugs; and CT-P71 showed efficacy in supressing tumours of bladder, breast and lung cancer with excellent safety in toxicity tests.
Celltrion states that it plans to quickly enter into clinical trials and complete the development of a “best in class” drug.
This news follows Celltrion’s announcement in October 2024 of results of a global phase 3, 2-year follow-up study which found Zymfentra™ (infliximab) as monotherapy was just as effective and safe as when combined with immunosuppressants for patients with Crohn’s disease or ulcerative colitis.
In September 2024, Celltrion also announced that it presented the 52-week results of its Phase 3 trial of Eydenzelt™ (CT-P42), biosimilar to Regeneron’s Eylea® (aflibercept), at the European Society of Retina Specialists (EURETINA) which showed that Eydenzelt™ has comparable efficacy and safety to Eylea® over 52 weeks in patients with diabetic macula oedema (DME).